Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 75330-75-5] Lovastatin

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-N0504
Brand:	MCE
CAS:	75330-75-5

Overview

MDL	MFCD00072164
Molecular Weight	404.54
Molecular Formula	C24H36O5
SMILES	O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1

For research use only. We do not sell to patients.

14 Publications Citing Use of MCE

[1]Cell Metab. 2020 Apr 7;31(4):741-754.e5.
[2]Redox Biol. 2022 Feb;49:102207.
[3]Cell Death Dis. 2019 Apr 11;10(4):327.
[4]JCI Insight. 2022 Aug 9;e161940.
[5]Front Cell Dev Biol. 2022 Mar 3;10:806081.
[6]Front Cell Dev Biol. 2020 May 28;8:404.
[7]Antiviral Res. 2022 Dec 15;209:105497.
[8]PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.
[9]Cell Cycle. 2019 Dec;18(23):3337-3350.
[10]Front Bioeng Biotechnol. 2022 Mar 17;10:826093.
[11]J Gen Virol. 2019 Feb;100(2):156-165.
[12]Biochem Biophys Res Commun. 2019 May 14;512(4):736-741.
[13]ACS Omega. 2020 Nov 15;5(46):29935-29942.
[14]University of New Hampshire. Science in Biochemistry. 2021 Oct.

Summary

Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol .

IC50 & Target

HMG-CoA reductase ^[1]

In Vitro

Lovastatin (10 μM; 72 hours) efficiently reduces viability of HepG2 cells ^[2] .
Lovastatin (10 μM; 48 hours) induces apoptosis in HepG2 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	HepG2 cells
Concentration:	10 μM
Incubation Time:	72 hours
Result:	Efficiently reduced viability of HepG2 cells.

In Vivo

Lovastatin is an inactive lactone that is hydrolyzed in the liver to an active f3-hydroxyacid form. This principal metabolite is the inhibitor of the enzyme HMG-CoA reductase. The K _i is 1 nM. Lovastatin and its β-hydroxyacid metabolite are highly bound to human plasma proteins. Lovastatin crosses the blood-brain and placental barriers ^[3] . Lovastatin produces a profound reduction of apolipoprotein-B-containing lipoproteins, especially LDL cholesterol and, to a lesser extent, plasma triglycerides, and a small increase in HDL cholesterol ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03510715	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolemia	August 31, 2018	Phase 3
NCT01250535	University of North Carolina, Chapel Hill\|National Institutes of Health (NIH)	Healthy Volunteers\|Drug Drug Interactions	December 2010	Phase 1
NCT00583102	University of Iowa	Acute Myeloid Leukemia	June 2001	Phase 1\|Phase 2
NCT00132717	Organon and Co	Hypercholesterolemia	January 1, 2005	Phase 3
NCT02518503	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Diabetes Mellitus, Type 2\|Cardiovascular Disease	July 2012
NCT00741013	Washington University School of Medicine\|Barnes-Jewish Hospital	Lung Inflammation	March 2007	Early Phase 1
NCT00000512	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Arteriosclerosis\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia	January 1984	Phase 3
NCT04297033	Beijing Tiantan Hospital	Cerebral Arteriovenous Malformation	January 1, 2021	Phase 2
NCT00243880	Columbia University	Stroke	September 2005	Phase 1
NCT03981601	Islamic Azad University, Tehran	Bone Loss	February 22, 2018	Phase 2
NCT00352599	University of California, Los Angeles	Neurofibromatosis 1	September 2009	Phase 1
NCT01976936	Mitchell S Elkind\|National Institute of Neurological Disorders and Stroke (NINDS)\|Columbia University	Stroke\|Rhabdomyolysis\|Jaundice	February 2009	Phase 2
NCT00585052	University of Iowa	Ovarian Cancer	August 2003	Phase 2
NCT00584012	Susan L Roeder\|University of Iowa	Any Cancer\|Breast Cancer	April 2004	Phase 1
NCT00092846	Merck Sharp & Dohme LLC	Hypercholesterolemia	December 4, 2002	Phase 3
NCT00685685	Mutual Pharmaceutical Company, Inc.	Healthy	September 2004	Phase 1
NCT02603770	Luye Pharma Group Ltd.	Lipid Metabolism Disorder	November 2015	Phase 1
NCT00004346	National Center for Research Resources (NCRR)\|Oregon Health and Science University	Cerebrotendinous Xanthomatosis	January 1996	Phase 2
NCT00700921	National Jewish Health\|National Heart, Lung, and Blood Institute (NHLBI)	Chronic Obstructive Pulmonary Disease (COPD)	April 2008	Phase 2
NCT03178526	Islamic Azad University, Tehran	Alveolar Bone Loss, Chronic Periodontitis, Lovestatin Gel, Regeneration	December 24, 2015	Phase 2\|Phase 3
NCT00000463	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia	April 1987	Phase 3
NCT00000469	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Carotid Stenosis\|Cerebral Arteriosclerosis\|Cerebrovascular Disorders\|Heart Diseases\|Vascular Diseases	May 1988	Phase 2
NCT02518516	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Hypercholesterolemia	January 2011
NCT03242499	National Taiwan University Hospital	Parkinson Disease	May 15, 2017	Phase 2
NCT00116870	Merck Sharp & Dohme LLC\|National Institute on Aging (NIA)	Atherosclerosis\|Coronary Artery Disease	June 1985	Phase 2\|Phase 3
NCT00580970	Virginia Commonwealth University\|Hunter Holmes Mcguire Veteran Affairs Medical Center	Prostate Cancer	April 2007	Phase 2
NCT00721305	Universidad de Antioquia\|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)\|Laboratorio Clínico Congregación Mariana\|Laboratorios Laproff S.A.\|Humax Pharmaceutical	HIV Seropositivity	August 2008	Phase 2
NCT02563860	Montefiore Medical Center\|Rett Syndrome Research Trust	Rett Syndrome	July 2015	Phase 2
NCT01478828	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Patrick C Walsh Prostate Cancer Research Fund	Prostate Cancer	July 13, 2012	Not Applicable
NCT00071266	Kos Pharmaceuticals	Intermittent Claudication\|Peripheral Vascular Disease	October 2003	Phase 3
NCT00302952	National Institute of Allergy and Infectious Diseases (NIAID)\|Autoimmunity Centers of Excellence	Rheumatoid Arthritis	November 6, 2007	Phase 2
NCT00963664	NeoPlas Innovation	Melanoma\|Malignant Melanoma	December 2009	Phase 2
NCT02642653	University of California, Davis	Fragile X Syndrome\|Genetic Diseases	January 2016	Phase 4
NCT03826940	University of Coimbra	Autism Spectrum Disorder\|Neurofibromatosis 1	February 19, 2019	Not Applicable
NCT01110642	Northwestern University	Syndromic Ichthyoses\|CHILD Syndrome\|Smith Lemli Opitz Syndrome\|Conradi Syndrome	July 2011	Phase 2
NCT04359823	Medical University of South Carolina	Actinic Porokeratosis	August 24, 2020	Phase 1\|Phase 2
NCT03510884	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolaemia	May 31, 2018	Phase 3
NCT00689806	University of Chicago	Severe Persistent Asthma		Phase 1\|Phase 2
NCT00902668	Virginia Commonwealth University	Breast Cancer\|Radiation Toxicity	April 2009	Phase 2
NCT01527669	National Taiwan University Hospital\|National Science Council, Taiwan	Healthy Subjects	February 2012	Phase 4
NCT02998151	Children´s Hospital Medical Center, Cincinnati\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Fragile X Syndrome	January 2016	Early Phase 1
NCT02964884	Vanderbilt University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Neurofibromatosis Type 1\|Learning Disability\|Reading Disability\|NF1	November 2016	Phase 2
NCT00000477	National Heart, Lung, and Blood Institute (NHLBI)	Atherosclerosis\|Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Hypercholesterolemia\|Myocardial Ischemia	July 1990	Phase 2
NCT02389868	Université de Sherbrooke	Blood Platelets Proteome	February 2015	Phase 2
NCT00285857	Stanford University	Breast Cancer	November 2005	Phase 2
NCT00462280	National Cancer Institute (NCI)	Precancerous Condition\|Stage 0 Melanoma\|Stage I Melanoma\|Stage II Melanoma	May 2007	Phase 2
NCT00853580	University of Alabama at Birmingham\|Boston Children´s Hospital\|Children´s Hospital of Philadelphia\|Children´s National Research Institute\|Children´s Hospital Medical Center, Cincinnati\|National Cancer Institute (NCI)\|University of Chicago\|University of Utah\|Washington University School of Medicine\|Sydney Children´s Hospitals Network\|University of Texas Southwestern Medical Center	Neurofibromatosis Type 1	July 2009	Phase 2
NCT00062556	Kos Pharmaceuticals	Intermittent Claudication\|Peripheral Vascular Disease	January 2003	Phase 3
NCT03504501	Technical University of Munich	Impaired Synaptic Plasticity\|Impaired Cognition	March 22, 2019	Phase 2
NCT00684723	Mutual Pharmaceutical Company, Inc.	Healthy	July 2004	Phase 1

Appearance

Solid

Source

aspergillus terreus

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 247.19 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4719 mL	12.3597 mL	24.7194 mL
5 mM	0.4944 mL	2.4719 mL	4.9439 mL
10 mM	0.2472 mL	1.2360 mL	2.4719 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J.
[2] Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83.
[3] Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48.
[4] Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
[5] Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55.

Synonyms

Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-

Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1α(R*),3α,7β,8β(2S*,4S*),8aβ]]-

Mevinolin

MSD 803

Monacolin K

Antibiotic MB 530B

MK 803

Monacolin K lactone

Lovastatin

Mevacor

L 154803

(+)-Mevinolin

6α-Methylcompactin

Sivlor

Mevlor

Lovalip

Mevinacor

Altocor

Lovastatin lactone

Lostatin

Lestric

Lovacard

Lovex

Altoprev

NSC 633781

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart